Scholar Rock gets first FDA nod for rare muscle-wasting disease ↧

Scholar Rock gets first FDA nod for rare muscle-wasting disease ↧ ↧ Scholar Rock gets first FDA nod for rare muscle-wasting disease The U.S. Food and Drug Administration approved Scholar Rock's therapy ​on Friday to treat a rare genetic condition that causes muscle ‌weakness, marking the first regulatory approval for the company.